Resources
47 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 5/17/2024
The Alcohol-Related Disease Impact (ARDI) is an online application from the Centers for Disease Control and Prevention (CDC) that provides national and state estimates of alcohol-related health impacts, including deaths and years of potential life lost (YPLL).
Posted 4/19/2024
April is Alcohol Awareness Month. This month offers a time to raise awareness and understanding of alcohol use and misuse. Resources and support is available for individuals struggling with alcohol use. In addition, the Substance Abuse and Mental Health Services Administration provides a social media toolkit for communities to utilize.
Posted 2/2/2024 (updated 3/28/2024)
The U.S. Department of Health and Human Services' Office of Minority Health provided a brief in November 2023 assessing whether and how rates of substance use and substance use disorder (SUD) among adults (ages 18 and older) differ by race and ethnicity.
Posted 12/1/2023 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration (SAMHSA) released results of the 2022 National Survey on Drug Use and Health (NSDUH). The NSDUH provides information on substance use and mental health rates in the United States with data on the self-reported use of tobacco, alcohol, and illicit drugs; substance use disorders; mental health conditions; and suicidal thoughts and behaviors. SAMSHA also released a high-level brief of the report with infographics.
Posted 8/18/2023 (updated 3/26/2024)
The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) held an event where health care professionals and federal partners discussed xylazine-related testing, treatment, and wound care. As the White House has deemed fentanyl adulterated with xylazine an emerging threat, it is important to identify and adapt to the rapidly changing practices of patient care.
Posted 7/26/2023 (updated 3/28/2024)
This breakout session provided insights from project leaders on how to respectfully collaborate with Indigenous communities. Furthermore, we shared the ways that the Community Conversations approach empowers individuals across communities to participate in and to lead change; supports recovery; and lays a foundation for current and future generations to live healthier lives.
Posted 5/30/2023 (updated 3/27/2024)
Overdose Detection Mapping and Application Program (ODMAP) is a free, web-based, overdose reporting platform. It is for local, state, federal, and tribal public safety and public health entities working in overdose response, reduction, and prevention.
Posted 3/21/2023 (updated 3/27/2024)
Researchers at Indiana University conducted one-on-one interviews with clinical providers and other stakeholders in the recovery arena to better understand the slow uptake of the drug most used to treat opioid use disorder. Biases against buprenorphine was the most consistent theme, though the reason for bias differed amongst stakeholders. Clinical providers and behavioral health care providers preferred the abstinence approach rather than use of medications.
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.
Posted 1/31/2023 (updated 3/27/2024)
The National Survey on Drug Use and Health (NSDUH) is conducted annual and provides nationally representative data on the use of substances (tobacco, alcohol, and drugs), substance use disorders, those who received substance use treatment, and mental health issues and services. This survey is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA).